1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 4: 
Univariate correlations between MR imaging measures of MS activity and burden of disease
Variable 1*Variable 2*All Patients (n = 239)Placebo Group (n = 120)GA Group (n = 119)
Baseline T2 LVOn-trial EL0.51 (<.001)0.55 (<.001)0.47 (<.001)
Baseline T2 LVOn-trial new T2 lesions0.32 (<.001)0.40 (<.001)0.24 (.009)
Baseline T2 LVT2 DLV0.37 (<.001)0.44 (<.001)0.30 (.001)
Baseline T2 LVT1 DLV0.50 (<.001)0.48 (<.001)0.53 (<.0001)
Baseline T1 LVOn-trial EL0.36 (<.001)0.41 (<.001)0.29 (.001)
Baseline T1 LVOn-trial new T2 lesions0.19 (.003)0.28 (.002)0.10
Baseline T1 LVT1 DLV0.29 (<.001)0.33 (<.001)0.24 (.009)
Baseline T1 LVT2 DLV0.17 (.007)0.22 (0.02)0.13
  • Note.—Values are the Spearman rank correlation coefficients. Data in parentheses are P values ≤.05.
  • * DLV indicates the difference in lesion volume between month 9 images and baseline images; LV, lesion volume; on-trial EL, the total number of Gd-enhancing lesions during the 9 months of the study.